EDIT Stock Analysis: Editas Medicine | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 497m USD | 12M Return: 47.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.28M
Qual. Beats: 0
Rev. Trend: 9.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Editas Medicine is a U.S.-based, clinical-stage biotechnology company that develops genomic medicines using a proprietary CRISPR-based gene editing platform. Its lead candidate, EDIT-401, is a one-time in vivo therapy aimed at lowering LDL cholesterol by upregulating the LDL receptor to treat hyperlipidemia. The companys pipeline also includes ex vivo gene editing programs for Sickle cell disease and transfusion-dependent beta-thalassemia, as well as broader in vivo medicines targeting additional cell and tissue types. Editas maintains a research collaboration with Juno Therapeutics focused on alpha-beta T-cell therapies for solid tumors, liquid tumors, and autoimmune diseases. As a clinical-stage biotech without commercialized products, the company is dependent on pipeline advancement, partnerships, and capital markets to fund operations. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas is listed on NASDAQ under the ticker EDIT and is classified within the GICS Biotechnology sub-industry.
- EDIT-401 LDL cholesterol therapy reports clinical trial milestone
- Cash runway tightens as development spending accelerates
- In vivo gene editing competition intensifies from Verve and Beam
| Net Income: -109.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.64 > 0.02 and ΔFCF/TA 24.75 > 1.0 |
| NWC/Revenue: 228.2% < 20% (prev 423.4%; Δ -195.2% < -1%) |
| CFO/TA -0.94 > 3% & CFO -140.5m > Net Income -109.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.9m) vs 12m ago 17.85% < -2% |
| Gross Margin: 3.74% > 18% (prev -118.3%; Δ 122.0% > 0.5%) |
| Asset Turnover: 18.74% > 50% (prev 13.59%; Δ 5.15% > 0%) |
| Interest Coverage Ratio: -8.57 > 6 (EBIT TTM -103.9m / Interest Expense TTM 12.1m) |
| A: 0.59 (Total Current Assets 128.1m - Total Current Liabilities 39.8m) / Total Assets 149.3m |
| B: -11.07 (Retained Earnings -1.65b / Total Assets 149.3m) |
| C: -0.50 (EBIT TTM -103.9m / Avg Total Assets 206.5m) |
| D: 0.03 (Book Value of Equity 4.41m / Total Liabilities 144.9m) |
| Altman-Z'' = -35.57 = D |
| DSRI: 3.0 (Receivables 2.59m/510k, Revenue 38.7m/35.8m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.25 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.08 (Revenue 38.7m / 35.8m) |
| TATA: 0.21 (NI -109.0m - CFO -140.5m) / TA 149.3m) |
| Beneish M = -1.15 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 3.75 with a total of 2,813,412 shares traded. Over the past week, the price has changed by +17.19%, over one month by +41.78%, over three months by +36.86% and over the past year by +47.64%.
Current recommended Stop Loss: 3.00 (which is 20% or 2.8 ATR below the current price).
Editas Medicine has received a consensus analysts rating of 3.47. Therefore, it is recommended to hold EDIT.
- StrongBuy: 4
- Buy: 1
- Hold: 8
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 5.8 | 54.1% |
P/S = 12.8503
P/B = 112.9727
Revenue TTM = 38.7m USD
EBIT TTM = -103.9m USD
EBITDA TTM = -100.1m USD
Long Term Debt = 57.8m USD (estimated: total debt 72.0m - short term 14.2m)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 89.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 17.3m
Net Debt = 12.9m USD (calculated: Debt 89.3m - CCE 76.4m)
Enterprise Value = 510.1m USD (497.2m + Debt 89.3m - CCE 76.4m)
Interest Coverage Ratio = -8.57 (Ebit TTM -103.9m / Interest Expense TTM 12.1m)
EV/FCF = -5.30x (Enterprise Value 510.1m / FCF TTM -96.2m)
FCF Yield = -18.87% (FCF TTM -96.2m / Enterprise Value 510.1m)
FCF Margin = -248.7% (FCF TTM -96.2m / Revenue TTM 38.7m)
Net Margin = -281.6% (Net Income TTM -109.0m / Revenue TTM 38.7m)
Gross Margin = 3.74% ((Revenue TTM 38.7m - Cost of Revenue TTM 37.2m) / Revenue TTM)
Gross Margin QoQ = 82.94% (prev none%)
Tobins Q-Ratio = 3.42 (Enterprise Value 510.1m / Total Assets 149.3m)
Interest Expense / Debt = 13.58% (Interest Expense 12.1m / Debt 89.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -82.1m (EBIT -103.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.90 (Total Current Assets 128.1m / Total Current Liabilities 44.1m)
Debt / Equity = 20.25 (Debt 89.3m / totalStockholderEquity, last quarter 4.41m)
Debt / EBITDA = -0.13 (negative EBITDA) (Net Debt 12.9m / EBITDA -100.1m)
Debt / FCF = -0.13 (negative FCF - burning cash) (Net Debt 12.9m / FCF TTM -96.2m)
Total Stockholder Equity = 16.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.76% (Net Income -109.0m / Total Assets 149.3m)
RoE = -677.4% (Net Income TTM -109.0m / Total Stockholder Equity 16.1m)
RoCE = -140.7% (out of range, set to none) (EBIT -103.9m / Capital Employed (Equity 16.1m + L.T.Debt 57.8m))
RoIC = -67.39% (negative operating profit) (NOPAT -82.1m / Invested Capital 121.8m)
WACC = 15.49% (E(497.2m)/V(586.5m) * Re(16.35%) + D(89.3m)/V(586.5m) * Rd(13.58%) * (1-Tc(0.21)))
Discount Rate = 16.35% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 8.36%
[DCF] Fair Price = unknown (Cash Flow -96.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.12 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 4.37% | SUE: -0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=-30.60% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.28 | Chg30d=+4.19% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.00 | Chg30d=+5.81% | Revisions=+22% | GrowthEPS=+44.7% | GrowthRev=-64.6%
EPS next Year (2027-12-31): EPS=-0.94 | Chg30d=-8.53% | Revisions=+29% | GrowthEPS=+6.0% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +24% (up=9, down=5)